# BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 P&L / Income Statement

- Company: BridgeBio Pharma, Inc. (BBIO)
- Period: 2026-07-01 to 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0001743881-26-000034
- Page: https://plicit.ai/financials/bbio/fy2026-q3-income-statement
- Chart image: https://plicit.ai/charts/bbio-fy2026-q3-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-07-01 through 2026-09-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues, net**: 353,171,000 US dollars
- **Total cost of revenues**: 20,450,000 US dollars
- **Gross profit (calculated)**: 332,721,000 US dollars
- **Operating expenses (calculated)**: 344,360,000 US dollars
- **Loss from operations**: negative 11,639,000 US dollars
- **Total other expense, net**: negative 47,628,000 US dollars
- **Loss before income taxes**: negative 59,267,000 US dollars
- **Provision for (benefit from) income taxes**: 1,229,000 US dollars
- **Net loss**: negative 60,496,000 US dollars
- **Net product revenue**: 253,346,000 US dollars
- **License and services revenue**: 79,314,000 US dollars
- **Royalty revenue**: 20,511,000 US dollars
- **Restructuring, impairment, and related charges**: 0 US dollars
- **Research and development**: 143,506,000 US dollars
- **Selling, general and administrative**: 200,854,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BridgeBio Pharma, Inc.: −$56.71 M; to noncontrolling interests: −$3.79 M.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/bbio/fy2026-q3-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/bbio-fy2026-q3-revenue-by-geography-sankey.png

Income statement for 2026-07-01 through 2026-09-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues, net**: 353,171,000 US dollars
- **Total cost of revenues**: 20,450,000 US dollars
- **Gross profit (calculated)**: 332,721,000 US dollars
- **Operating expenses (calculated)**: 344,360,000 US dollars
- **Loss from operations**: negative 11,639,000 US dollars
- **Total other expense, net**: negative 47,628,000 US dollars
- **Loss before income taxes**: negative 59,267,000 US dollars
- **Provision for (benefit from) income taxes**: 1,229,000 US dollars
- **Net loss**: negative 60,496,000 US dollars
- **UNITED STATES (calculated)**: 253,223,607 US dollars
- **Asia Pacific (calculated)**: 2,472,197 US dollars
- **EMEA (calculated)**: 97,475,196 US dollars
- **Restructuring, impairment, and related charges**: 0 US dollars
- **Research and development**: 143,506,000 US dollars
- **Selling, general and administrative**: 200,854,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BridgeBio Pharma, Inc.: −$56.71 M; to noncontrolling interests: −$3.79 M.

## Chart details: Revenue by Business Segment by Product and Service

- Page: https://plicit.ai/financials/bbio/fy2026-q3-income-statement/revenue-by-business-segment-by-product-and-service
- Chart image: https://plicit.ai/charts/bbio-fy2026-q3-revenue-by-business-segment-by-product-and-service-sankey.png

Income statement for 2026-07-01 through 2026-09-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues, net**: 353,171,000 US dollars
- **Total cost of revenues**: 20,450,000 US dollars
- **Gross profit (calculated)**: 332,721,000 US dollars
- **Operating expenses (calculated)**: 344,360,000 US dollars
- **Loss from operations**: negative 11,639,000 US dollars
- **Total other expense, net**: negative 47,628,000 US dollars
- **Loss before income taxes**: negative 59,267,000 US dollars
- **Provision for (benefit from) income taxes**: 1,229,000 US dollars
- **Net loss**: negative 60,496,000 US dollars
- **Reportable Segment - License and services revenue**: 79,314,000 US dollars
- **Reportable Segment - Net product revenue**: 253,346,000 US dollars
- **Reportable Segment - Royalty revenue**: 20,511,000 US dollars
- **Restructuring, impairment, and related charges**: 0 US dollars
- **Research and development**: 143,506,000 US dollars
- **Selling, general and administrative**: 200,854,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BridgeBio Pharma, Inc.: −$56.71 M; to noncontrolling interests: −$3.79 M.

## Key Takeaways

- Revenue reached $353.17 M, up from $120.70 M, and the company still lost $60.50 M in the quarter.
- Of the quarter's $232.47 M sales rise, 32% came from one $75.0 M Bayer sales milestone.
- Research, selling and overhead costs took $344.36 M, more than the $332.72 M gross profit.
- Research spending fell to 40.6% of sales this quarter, from 93.5% a year earlier.

## The Unvarnished Truth

### BridgeBio's sales rose 193%, yet the quarter still lost money

BridgeBio's sales rose 193% this quarter, to $353.17 M, and the headline looks like a turnaround. Look under the total. Net product revenue reached $253.35 M, a real gain. The filing says the license line's rise came mainly from a $75.0 M sales milestone under the Bayer License Agreement. That one milestone was 32% of the quarter's $232.47 M rise in sales. Over nine months, license and services revenue actually fell 29%, from $125.44 M to $89.54 M. Without the milestone, the loss would have been about $135.50 M, all else equal.

Why does the loss survive a surge in sales? Research, selling and overhead costs took $344.36 M, more than the $332.72 M of gross profit left after direct costs. Management says the research increase is primarily driven by late-stage programs. The larger drag sits below the operating line, at $42.28 M of noncash interest on deferred royalty obligations, which the filing treats as debt owed to royalty purchasers. That charge is not paid in cash, so it widens the loss without draining the bank account.

What it means: the product line is the real engine, up 134% to $253.35 M, but it does not yet carry the whole cost base. The milestone was a single event, so the quarter's growth rate cannot be read as a run rate. Interest on its debt and royalty obligations ran $55.54 M in the quarter, on top of the operating loss. Nine months of product sales show the same pattern, with license income swinging while product revenue keeps climbing. Will product sales alone cover research, overhead and interest in a quarter with no milestone?

## Intelligent Insights for Investors

### Did BridgeBio make a profit this period?

No. BridgeBio lost $60.50 M this quarter, or 17 cents of every sales dollar. Its operating result was a loss of $11.64 M, before interest and other items.

### Do BridgeBio's numbers back up its explanation for its sales change?

Mostly. Net product revenue added $145.24 M of the $232.47 M rise in sales. The filing says the license line's rise came mainly from a $75.0 M sales milestone under the Bayer License Agreement.

## Intelligent Insights for Lenders

### Does BridgeBio earn enough to cover its interest payments?

No. Its operating result was a loss of $11.64 M this quarter, against $13.26 M of interest expense. A year earlier the operating loss was $145.20 M, against $11.74 M of interest.

## Intelligent Insights for Employees

### What is BridgeBio's biggest expense?

Selling, general and administrative expense is the largest, at $56.87 of every $100 of sales this quarter. Research and development comes second, at $40.63 of every $100.
